Phenotypic Characterization of Subsets of T Cell Lymphoma: Towards a Functional Classification of T Cell Lymphoma

References

• Lennert K., Feller A. C. Histopathology of Non-Hodgkin's lymphoma. Springer-Verlag, New York 1992; 196–210
   Google Scholar
• Nakamura S., Suchi T., Koshikawa T., Suzuki H., Oyama A., Kojima M., Motoori T., Ueda R., Takahashi T. Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 1993; 72: 1762–1772
   PubMed Web of Science ®Google Scholar
• Suchi T., Lennert K., Tu L.-Y, Kikuchi M., Sato E., Stansfeld A. G., Feller A. C. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol 1987; 40: 995–1015
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K.C., Cleary M. L., Delsol G., DeWolf-Peeters C., Falini B., Gatter K. C., Grogan T. M., Issacson P. G., Knowles D. M., Mason D. Y., Muller-Hermelink H.-K., Pileri S. A., Piris M. A., Ralfkiaer E., Warnke R. A. A revised European-America Classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Habermann T. M., Kurtin P. J., Witzig T. E., Chen M. G., Li C. Y., Inwards D. J., Colgan J. P. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296–2301
   PubMed Web of Science ®Google Scholar
• Anderson J. R., Armitage J. O., Weisenburger D. D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A., Cid J., Salar A., Lopez A., Montalban C., Castrillo J. M., Gonzalez M., Ribera J. M., Brunei S., Garcia-Conde J., Fernandez de Sevilla A., Bosch F., Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849–855
   PubMed Web of Science ®Google Scholar
• Wood K. M., Pallesen G., Ralfkiaer E., Warnke R., Gatter K. C., Mason D.Y. Heterogeneity of CD3 antigen expression in T-cell lymphoma. Histopathology 1993; 22: 311–317
   PubMed Web of Science ®Google Scholar
• Hastrup N., Ralfkiaer E., Pallesen G. Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol 1989; 42: 398–402
   PubMed Web of Science ®Google Scholar
• Moll M., Reinhold U., Kukel S., Abken H., Muller R., Oltermann I., Kreysel H. W. CD7-negative helper T cells accumulate in inflammatory skin lesions. J Invest Dermatol 1994; 102: 328–332
   PubMed Web of Science ®Google Scholar
• Reinhold U., Liu L., Sesterhenn J., Abken H. CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells. Immunology 1996; 89: 391–396
   PubMed Web of Science ®Google Scholar
• Smith K. J., Skelton H. G., Chu W. S., Yeager J., Angritt P., Wagner K. F. Decreased CD7 expression in cutaneous infiltrates of HIV-1+ patients. Military Medical Con sortium for the Advancement of Retroviral Research (MMCARR). Am J Dermatopathol 1995; 17: 564–569
   PubMed Web of Science ®Google Scholar
• Scala E., Russo G., Cadoni S., Narducci M. G., Girardelli C. R., De Pita O., Puddu P. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7-T helper lymphocytes expansion [In Process Citation]. J Invest Dermatol 1999; 113: 622–627
   PubMed Web of Science ®Google Scholar
• McClanahan J., Fukushima R. I., Stetler-Stevenson M. Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: a diagnoistic dlilemma in flow cytometry. Cytometry 1999; 38: 280–285
   PubMedGoogle Scholar
• Harmon C. B., Witzig T. E., Katzmann J. A., Pittelkow M. R. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996; 35: 404–410
   PubMed Web of Science ®Google Scholar
• Miyachi H., Tanaka Y., Gondo K., Kawada T., Kato S., Sasao T., Hotta T., Oshima S., Ando Y. Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia. Am J Hematol 1999; 62: 159–164
   PubMed Web of Science ®Google Scholar
• Yamashita Y., Yatabe Y., Tsuzuki T., Nakayama A., Hasegawa Y., Kojima H., Nagasawa T., Mori N. Perform and granzyme expression in cytotoxic T-cell lymphomas. Mod Pathol 1998; 11: 313–323
   PubMed Web of Science ®Google Scholar
• Berti E., Tomasini D., Vermeer M. H., Meijer C. J., Alessi E., Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: A distinct clinicopathological entity with an Aggressive Clinical behavior. Am J Pathol 1999; 155: 483–492
   PubMed Web of Science ®Google Scholar
• de Bruin P. C., Connolly C. E., Oudejans J. J., Kummer J. A., Jansen W., McCarthy C. F., Meijer C. J. Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype [published erratum appears in Histopathology 1997 Dec;31(6):578]. Histopathology 1997; 31: 313–317
   PubMed Web of Science ®Google Scholar
• Daum S., Foss H. D., Anagnostopoulos I., Dederke B., Demel G., Araujo I., Riecken E. O., Stein H. Expression of cytotoxic molecules in intestinal T-cell lymphomas. The German Study Group on Intestinal Non-Hodgkin Lymphoma. J Pathol 1997; 182: 311–317
   PubMed Web of Science ®Google Scholar
• Kumar S., Krenacs L., Medeiros J., Elenitoba-Johnson K. S., Greiner T. C., Sorbara L., Kingma D. W., Raffeld M., Jaffe E. S. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998; 29: 397–403
   PubMed Web of Science ®Google Scholar
• Kagami Y., Suzuki R., Taji H., Yatabe Y., Takeuchi T., Maeda S., Kondo E., Kojima M., Motoori T., Mizoguchi Y., Okamoto M., Ohnishi K., Yamabe H., Seto M., Ogura M., Koshikawa T., Takahashi T., Kurita S., Morishima Y., Suchi T., Nakamura S. Nodal cytotoxic lymphoma spectrum: a Clinicopathologic study of 66 patients [In Process Citation]. Am J Surg Pathol 1999; 23: 1184–1200
   PubMed Web of Science ®Google Scholar
• Dukers D. F., ten Berge R. L., Oudejans J. J., Pulford K., Hayes D., Misere J. F., Ossenkoppele G. J., Jaspars L. H., Willemze R., Meijer C. J. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol 1999; 52: 129–136
   PubMed Web of Science ®Google Scholar
• Kanavaros P., Vlychou M., Stefanaki K., Rontogianni D., Gaulard P., Pantelidaki E., Zois M., Darivianaki K., Georgoulias V., Boulland M. L., Gorgoulis V., Kittas C. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. Anticancer Res 1999; 19: 1209–1216
   PubMed Web of Science ®Google Scholar
• Chan A. C., Ho J. W., Chiang A. K., Srivastava G. Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association. Histopathology 1999; 34: 16–24
   PubMed Web of Science ®Google Scholar
• Boulland M. L., Kanavaros P., Wechsler J., Casiraghi O., Gaulard P. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. J Pathol 1997; 183: 432–439
   PubMed Web of Science ®Google Scholar
• Rutella S., Rumi C., Lucia M. B., Etuk B., Cauda R., Leone G. Flow cytometric detection of perform in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. Immunol Lett 1998; 60: 51–55
   PubMed Web of Science ®Google Scholar
• Zola H., Flego L., Macardle P. J., Donohoe P. J., Ranford J., Roberton D. The CD45RO (p180, UCHL1) marker: complexity of expression in peripheral blood. Cell Immunol 1992; 145: 175–186
   PubMed Web of Science ®Google Scholar
• Demeure C. E., Byun D. G., Yang L. P., Vezzio N., Delespesse G. CD31 (PECAM-1) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Immunology 1996; 88: 110–115
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Dower S. K. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404
   PubMed Web of Science ®Google Scholar
• Chiarle R., Podda A., Prolla G., Podack E. R., Thorbecke G. J., Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999; 163: 194–205
   PubMed Web of Science ®Google Scholar
• Heath W. R., Kurts C., Caminschi I., Carbone F. R., Miller J. F. CD30 prevents T-cell responses to non-lymphoid tissues [In Process Citation]. Immunol Rev 1999; 169: 23–29
   PubMed Web of Science ®Google Scholar
• Gilfillan M. C., Noel P. J., Podack E. R., Reiner S. L., Thompson C. B. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998; 160: 2180–2187
   PubMed Web of Science ®Google Scholar
• Arch R. H., Thompson C. B. 4–1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18: 558–565
   PubMed Web of Science ®Google Scholar
• Gravestein L. A., Amsen D., Boes M., Calvo C. R., Kruisbeek A. M., Borst J. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol 1998; 28: 2208–2216
   PubMed Web of Science ®Google Scholar
• Martinez O. M., Villanueva J., Abtahi S., Beatty P. R., Esquivel C. O., Krams S. M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998; 65: 1240–1247
   PubMed Web of Science ®Google Scholar
• Okumura M., Hidaka Y., Matsuzuka F., Takeoka K., Tada H., Kuma K., Amino N. CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. Thyroid 1999; 9: 333–339
   PubMed Web of Science ®Google Scholar
• Vinante R., Krampera M., Morosato L., Rigo A., Romagnani S., Pizzolo G. Peripheral T lymphocyte cytokine profile (IFNg, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999; 84: 683–689
   PubMed Web of Science ®Google Scholar
• Minguela A., Marin L., Torio A., Muro M., Ontanon J., Alemany J. M., Sanchez-Bueno F., Parrilla P., Alvarez-Lopez M. R. CD30+ and CD27-lymphocytes in liver transplant: Th2 cytokine secretion. Transplant Proc 1999; 31: 516–518
   PubMed Web of Science ®Google Scholar
• Kobayashi M., Kobayashi H., Herndon D. N., Pollard R. B., Suzuki F. Burn-associated Candida albicans infection caused by CD30+ type 2 T cells. J Leukoc Biol 1998; 63: 723–731
   PubMed Web of Science ®Google Scholar
• Rizzardi G. P., Marriott J. B., Cookson S., Lazzarin A., Dalgleish A. G., Barcellini W. Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Thl/Th2-type response. Clin Exp Immunol 1998; 114: 61–65
   PubMed Web of Science ®Google Scholar
• Bamford K. B., Fan X., Crowe S. E., Leary J. F., Gourley W. K., Luthra G. K., Brooks E. G., Graham D. Y., Reyes V. E., Ernst P. B. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998; 114: 482–492
   PubMed Web of Science ®Google Scholar
• Seko Y., Takahashi N., Oshima H., Shimozato O., Akiba H., Kobata T., Yagita H., Okumura K., Azuma M., Yazaki Y. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by Coxsackie virus B3. J Pathol 1999; 188: 423–430
   PubMed Web of Science ®Google Scholar
• Krampera M., Vinante F., Tavecchia L., Morosato L., Chilosi M., Romagnani S., Zanolin M. E., Pizzolo G. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999; 117: 291–297
   PubMed Web of Science ®Google Scholar
• Ellis T. M., Simms P. E., Slivnick D. J., Jack H. M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993; 151: 2380–2389
   PubMed Web of Science ®Google Scholar
• Scala E., Carbonari M., Del Porto P., Cibati M., Tedesco T., Mazzone A. M., Paganelli R., Fiorilli M. Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. J Immunol 1998; 161: 489–493
   PubMed Web of Science ®Google Scholar
• Alzona M., Jack H. M., Fisher R. I., Ellis T. M. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994; 153: 2861–2867
   PubMed Web of Science ®Google Scholar
• Zhou Z., Kim S., Hurtado J., Lee Z. H., Kim K. K., Pollok K. E., Kwon B. S. Characterization of human homologue of 4-IBB and its ligand. Immunol Lett 1995; 45: 67–73
   PubMed Web of Science ®Google Scholar
• Pollok K. E., Kim S. H., Kwon B. S. Regulation of 4—IBB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. Eur J Immunol 1995; 25: 488–494
   PubMed Web of Science ®Google Scholar
• Lee Z. H., Kim Y. J., Wilde C. 4–1BB is expressed on CD45hi/ROhi transitional T cells in humans. Cell Immunol 1996; 169: 91–98
   PubMed Web of Science ®Google Scholar
• Garni-Wagner B. A., Lee Z. H., Kim Y. J., Wilde C., Kang C. Y., Kwon B. S. 4–1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol 1996; 169: 91–98
   PubMed Web of Science ®Google Scholar
• Kim Y. J., Kim S. H., Mantel P., Kwon B. S. Human 4—IBB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol 1998; 28: 881–890
   PubMed Web of Science ®Google Scholar
• Tan J. T., Whitmire J. K., Ahmed R., Pearson T. C., Larsen C. P. 4–1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 1999; 163: 4859–4868
   PubMed Web of Science ®Google Scholar
• Kobata T., Agematsu K., Kameoka J., Schlossman S. F., Morimoto C. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol 1994; 153: 5422–5432
   PubMed Web of Science ®Google Scholar
• Baum P. R., Gayle R. B.d., Ramsdell F., Srinivasan S., Sorensen R. A., Watson M. L., Seldin M. F., Clifford K. N., Grabstein K., Alderson M. R., et al. Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Circ Shock 1994; 44: 30–34
   PubMedGoogle Scholar
• Kaleeba J. A., Offner H., Vandenbark A. A., Lublinski A., Weinberg A. D. The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int Immunol 1998; 10: 453–461
   PubMed Web of Science ®Google Scholar
• Mallett S., Fossum S., Barclay A. N. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor. Embo J. 1990; 9: 1063–1068
   PubMed Web of Science ®Google Scholar
• Walker L., Gulbranson-Judge A., Flynn S., Brocker T., Raykundalia C., Goodall M. R.F., Lipp M., Lane P. Compromised OX40 Function in CD28-deficient Mice Is Linked with Failure to Develop CXC Chemokine Receptor 5-positive CD4 Cells and Germinal Centers. J Exp Med 1999; 190: 1115–1122
   PubMed Web of Science ®Google Scholar
• Brocker T., Gulbranson-Judge A., Flynn S., Riedinger M., Raykundalia C., Lane P. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 1999; 29: 1610–1616
   PubMed Web of Science ®Google Scholar
• Flynn S., Toellner K. M., Raykundalia C., Goodall M., Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188: 297–304
   PubMed Web of Science ®Google Scholar
• Kopf M., Ruedl C., Schmitz N., Gallimore A., Lefrang K., Ecabert B., Odermatt B., Bachmann M. F. OX40-Deficient Mice Are Defective in Th Cell Proliferation but Are Competent in Generating B Cell and CTL Responses after Virus Infection. Immunity 1999; 11: 699–708
   PubMed Web of Science ®Google Scholar
• Pippig S. D., Pena-Rossi C., Long J., Godfrey W. R., Fowell D. J., Reiner S. L., Birkeland M. L., Locksley R. M., Barclay A. N., Killeen N. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40) [In Process Citation]. J Immunol 1999; 163: 6520–6529
   PubMed Web of Science ®Google Scholar
• Chen A. I., McAdam A. J., Buhlmann J. E., Scott S., Lupher M., Jr., Greenfield E. A., Baum P. A., Fanslow W. C., Calderhead D. M., Freeman G.J. A.S. Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell: T Cell Interactions. Immunity 1999; 11: 689–698
   PubMed Web of Science ®Google Scholar
• Ohshima Y., Yang L. P., Uchiyama T., Tanaka Y., Baum P., Sergerie M., Hermann P., Delespesse G. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998; 92: 3338–3345
   PubMed Web of Science ®Google Scholar
• Delespesse G., Ohshima Y., Yang L. P., Demeure C., Sarfati M. OX40-Mediated cosignal enhances the maturation of naive human CD4+ T cells into high IL-4-producing effectors. Int Arch Allergy Immunol 1999; 118: 384–386
   PubMed Web of Science ®Google Scholar
• Guinn B. A., DeBenedette M. A., Watts T. H., Berinstein N. L. 4–1BBL cooperates with B7–1 and B7–2 in convening a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162: 5003–5010
   PubMed Web of Science ®Google Scholar
• DeBenedette M. A., Wen T., Bachmann M. F., Ohashi P. S., Barber B. H., Stocking K. L., Peschon J. J., Watts T. H. Analysis of 4–1BB ligand (4–1BBL)-deficient mice and of mice lacking both 4–1BBL and CD28 reveals a role for 4–1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza. virus. J Immunol 1999; 163: 4833–4841
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann R., Pickl W. F., Majdic O., Knapp W., Holler W. Crosslinking of CD27 in the presence of CD28 costimulation results in T cell proliferation and cytokine production. Cell Immunol 1995; 164: 20–27
   PubMed Web of Science ®Google Scholar
• Camerini D., Walz G., Loenen W. A., Borst J., Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147: 3165–3169
   PubMed Web of Science ®Google Scholar
• Tortorella C., Schulze-Koops H., Thomas R., Splawski J., Davis L., Picker L., Lipsky P. Expression of CD45RB and CD27 identifies subsets of CD4+ memory T cells with different capacities to induce B cell differentiation. J Immunol 1995; 155: 149–162
   PubMed Web of Science ®Google Scholar
• Weinberg A. D., Vella A. T., Croft M. OX-40: life beyond the effector T cell stage. Semin Immunol 1998; 10: 471–480
   PubMed Web of Science ®Google Scholar
• Gramaglia I., Weinberg A. D., Lemon M., Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161: 6510–6517
   PubMed Web of Science ®Google Scholar
• Jones D., Fletcher C. D., Pulford K., Shahsafaei A., Dorfman D. M. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood 1999; 93: 3487–3493
   PubMed Web of Science ®Google Scholar
• Masuda M., Ishida C., Arai Y., Okamura T., Ohsawa M., Shimakage M., Mizoguchi H. Dual action of CD30 antigen: anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells. Int J Hematol 1998; 67: 257–265
   PubMed Web of Science ®Google Scholar
• Mori M., Manuelli C., Pimpinelli N., Mavilia C., Maggi E., Santucci M., Bianchi B., Cappugi P., Giannotti B., Kadin M. E. CD30-CD30 Ligand Interaction in Primary Cutaneous CD30(+) T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression. Blood 1999; 94: 3077–3083
   PubMed Web of Science ®Google Scholar
• Imura A., Hori T., Imada K., Kawamata S., Tanaka Y., Imamura S., Uchiyama T. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 1997; 89: 2951–2958
   PubMed Web of Science ®Google Scholar
• Ryffel B., Brockhaus M., Durmuller U., Gudat F. Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha. Am J Pathol 1991; 139: 7–15
   PubMed Web of Science ®Google Scholar
• Koubek K., Stary J., Kumberova A., Klamova H., Filipec M. Occurrence of cytokine receptors on different lymphoid leukaemic cells. Eur J Haematol 1999; 63: 1–10
   PubMed Web of Science ®Google Scholar
• Nguyen P. L., Harris N. L., Ritz J., Robertson M. J. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease [published erratum appears in Am J Pathol 1996 Jul;149(l):346]. Am J Pathol 1996; 148: 847–853
   PubMed Web of Science ®Google Scholar
• Ng C. S., Lo S. T., Chan J. K. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. Hum Pathol 1999; 30: 48–53
   PubMed Web of Science ®Google Scholar
• Paulli M., Berti E., Boveri E., Kindl S., Bonoldi E., Gambini C., Rosso R., Borroni G., Straccapansa V., Magrini U., DeCoteau J. E., Krammer P. H., Moller P., Kadin M. E. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998; 29: 1223–1230
   PubMed Web of Science ®Google Scholar
• van Oers M. H., Pals S. T., Evers L. M., van der School C. E., Koopman G., Bonfrer J. M., Hintzen R. Q., von dem Borne A. E., van Lier R. A. Expression and release of CD27 in human B-cell malignancies. Blood 1993; 82: 3430–3436
   PubMed Web of Science ®Google Scholar
• Widney D., Gundapp G., Said J. W., van der Meijden M., Bonavida B., Demidem A., Trevisan C., Taylor J., Detels R., Mart#nez-Maza O. Aberrant Expression of CD27 and Soluble CD27 (sCD27) in HIV Infection and in AIDS-Associated Lymphoma. Clin Immunol 1999; 93: 114–123
   PubMed Web of Science ®Google Scholar
• Erlichman B., Howard O. M. CD27 signals through PKC in human B cell lymphomas. Cytokine 1999; 11: 476–484
   PubMed Web of Science ®Google Scholar
• Berti E., Cerri A., Cavicchini S., Delia D., Soligo D., Alessi E., Caputo R. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol 1991; 96: 718–723
   PubMed Web of Science ®Google Scholar
• Carbone A., Gloghini A., Zagonel V., Aldinucci D., Gattei V., Degan M., Improta S., Sorio R., Monfardini S., Pinto A. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 1995; 86: 4617–4626
   PubMed Web of Science ®Google Scholar